Through the 90-day period concluding January 10, 2026, Larimar Therapeutics's top three insider stakeholders include Director James E Flynn (7.32Mn shares), Director Thomas Edward Hamilton (507.59K shares), President And Ceo Carole Ben-Maimon (387.21K shares).
| Holder | Position | Shares | Report Date |
|---|---|---|---|
| James E Flynn | 7,321,129 | 04 Aug, 2025 | |
| Thomas Edward Hamilton | 507,590 | 20 Sep, 2022 | |
| Carole Ben-Maimon | President And Ceo | 387,208 | 24 Jan, 2025 |
| Michael Celano | Chief Financial Officer | 178,181 | 24 Jan, 2025 |
| Gopi Shankar | Chief Development Officer | 50,806 | 24 Jan, 2025 |
| Russell Clayton | Chief Medical Officer | 45,806 | 24 Jan, 2025 |
| Joseph Truitt | 2,750 | 18 May, 2023 | |
| Frank E Thomas | 2,000 | 15 Feb, 2024 |
* Please note that the shares above only reflect shares from the fund portfolio and the institutional portfolio. Shares from the personal portfolio are excluded from this Institutional Ownership Page. See these insiders' latest transactions here on Insider Page.
| Transaction Date | Insider Name | Security Class | Transaction Type | Shares Traded | Price | Shares Remaining | Ownership | Code |
|---|---|---|---|---|---|---|---|---|
| 31 Jul, 2025 | James E Flynn | Common Stock | A | 3,387,539 | $3.20 | 9,538,945 | I | P |
| 31 Jul, 2025 | James E Flynn | Common Stock | A | 3,387,529 | $3.20 | 9,538,918 | I | P |
| 31 Jul, 2025 | James E Flynn | Common Stock | A | 2,599,932 | $3.20 | 7,321,129 | I | P |
| 22 Jan, 2025 | Michael Celano | Common Stock | A | 34,185 | $0.00 | 178,181 | D | A |
| 22 Jan, 2025 | Michael Celano | - | - | 178,181 | D | |||
| 22 Jan, 2025 | Carole Ben-Maimon | Common Stock | A | 91,000 | $0.00 | 387,208 | D | A |
| 22 Jan, 2025 | Russell Clayton | Common Stock | A | 23,306 | $0.00 | 45,806 | D | A |
| 22 Jan, 2025 | Gopi Shankar | Common Stock | A | 23,306 | $0.00 | 50,806 | D | A |
| 16 Feb, 2024 | James E Flynn | - | - | 6,151,406 | I | |||
| 16 Feb, 2024 | James E Flynn | Common Stock | A | 1,430,206 | $8.74 | 6,151,389 | I | P |
| 16 Feb, 2024 | James E Flynn | Common Stock | A | 1,430,206 | $8.74 | 6,151,406 | I | P |
| 16 Feb, 2024 | James E Flynn | - | - | 4,207,982 | I | |||
| 16 Feb, 2024 | James E Flynn | Common Stock | A | 1,430,205 | $8.74 | 4,207,982 | I | P |
| 16 Feb, 2024 | James E Flynn | - | - | 6,151,389 | I | |||
| 14 Feb, 2024 | Frank E Thomas | - | - | 2,000 | D | |||
| 14 Feb, 2024 | Frank E Thomas | Common Stock | A | 2,000 | $11.00 | 2,000 | D | P |
| 17 Jan, 2024 | Michael Celano | Common Stock | A | 31,250 | $0.00 | 143,996 | D | A |
| 17 Jan, 2024 | Carole Ben-Maimon | Common Stock | A | 66,125 | $0.00 | 332,954 | D | A |
| 17 Jan, 2024 | Russell Clayton | Common Stock | A | 22,500 | $0.00 | 22,500 | D | A |
| 17 Jan, 2024 | Gopi Shankar | Common Stock | A | 22,500 | $0.00 | 27,500 | D | A |